Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.
Also called NCT01322347
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 294 participants
- Registry
-
NCT01322347
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT01322347. Randomized; single masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-04-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)
- Condition
- Renal Failure Chronic Requiring Hemodialysis
- Intervention (Drug)
- Soluble Ferric Pyrophosphate (SFP)
- Intervention (Device)
- Standard dialysate
- Lead sponsor
- Rockwell Medical Technologies, Inc.
Record details
- Record id
cardio:ct-nct01322347- Content hash
fb9c6b37d19dac6ad93aa23ad6dfedd30127e0b443451cafc7e3590946d2f9ae